(Q53235017)

English

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo I

scientific article published on 7 June 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

based on heuristic

inferred from title

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

Massimo Di Nicola

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Liliana Devizzi

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Paolo Corradini

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Antonello Domenico Cabras

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

C Tarella

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

M Zanni

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

C Patti

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

R Calvi

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

A Pescarollo

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

V Zoli

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

A Fornari

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

D Novero

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

M Stella

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

A Comino

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

D Remotti

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

M Ponzoni

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

D Caracciolo

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

M Magni

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

M Boccadoro

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

M Bregni

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

A Gallamini

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

I Majolino

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

S Mirto

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

A M Gianni

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Gruppo Italiano Terapie Innovative nei Linfomi

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

7 June 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1802-1811

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17554382%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404781

0 references

Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow transplantation for lymphoma CR1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

High dose chemo-radiotherapy for sensitive tumors: is sequential better than concurrent drug delivery?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in pat

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatal central nervous system lesions emerging during anti-CD20 monoclonal antibody therapy (Rituximab) for a post transplantation Epstein Barr virus-linked lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404781

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53235017&oldid=1527275364"